Abstract
The 2012 treatment guideline for Kawasaki disease (KD) proposes several second- and third-line therapies for patients unresponsive to intravenous immunoglobulin (IVIG). However, there are still no definite treatment recommendations for refractory KD. In 2005 we used cyclosporin A (CsA) to treat a case of refractory KD, and in 2008 it was reported that functional polymorphism of inositol 1,4,5-trisphosphate 3-kinase-C (ITPKC) is associated with susceptibility to KD and the risk of developing coronary arterial lesions. Because ITPKC acts as a negative regulator of T-cell activation through the NFAT pathway, activated T cells may be important in KD. CsA suppresses the activity of T cells through the same pathway and might therefore be a promising candidate for treatment of refractory KD. Here, we summarize the results of our clinical trials of CsA for refractory KD and propose a new CsA treatment option for KD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol. 2012;22(3):216–21. http://dx.doi.org/10.2188/jea.JE20110126 PMID:22447211.
The Clinical Guideline for Medical Treatment of Acute Stage Kawasaki Disease from the Scientific Committee. Pediatr Cardiol Card Surg. 2012;28 Suppl 3:s1–28.
Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol. 2006;33(4):803–9. PMID:16583481.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43(3):211–17. http://dx.doi.org/10.1046/j.1442-200x.2001.01373.x PMID:11380911.
Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011;124(25):2822–8. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.028423 PMID:22104548.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8. http://dx.doi.org/10.1016/j.jpeds.2008.06.011 PMID:18672254.
Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 2004;14(1):43–7. http://dx.doi.org/10.3109/s10165-003-0264-3 PMID:17028804.
Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin a therapy. Pediatr Infect Dis J. 2001;20(6):635–7. http://dx.doi.org/10.1097/00006454-200106000-00022 PMID:11419513.
Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. PMID:18084290.
Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet. 2010;19(14):2898–906. http://dx.doi.org/10.1093/hmg/ddq176 PMID:20423928.
Onouchi Y, Suzuki Y, Suzuki H, Terai M, Yasukawa K, Hamada H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 2013;13(1):52–9. http://dx.doi.org/10.1038/tpj.2011.45 PMID:21987091.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30(10):871–6. http://dx.doi.org/10.1097/INF.0b013e318220c3cf PMID:21587094.
Japanese Kawasaki disease Research Committee. Diagnostic guidelines of Kawasaki disease (in Japanese). 5th ed. Tokyo: Japanese Kawasaki disease Research Committee; 2002.
Suzuki H, Suenaga T, Takeuchi T, Shibuta S, Yoshikawa N. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatr Int. 2010;52(5):785–9. http://dx.doi.org/10.1111/j.1442-200X.2010.03163.x PMID:20487370.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, et al. Inflammatory cytokine profiles during cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine. 2012;60(3):681–5. http://dx.doi.org/10.1016/j.cyto.2012.08.006 PMID:22944461.
Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161(3):506–12.e1.. http://dx.doi.org/10.1016/j.jpeds.2012.02.048 PMID:22484354.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan
About this chapter
Cite this chapter
Suzuki, H. (2017). Cyclosporin A for IVIG Nonresponders. In: Saji, B., Newburger, J., Burns, J., Takahashi, M. (eds) Kawasaki Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56039-5_20
Download citation
DOI: https://doi.org/10.1007/978-4-431-56039-5_20
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56037-1
Online ISBN: 978-4-431-56039-5
eBook Packages: MedicineMedicine (R0)